Therapy with dabigatran (Pradaxa) can be associated with severe hemorrhage. Idarucizumab (Praxbind) has been approved as an antidote for dabigatran-related bleeding.
Dabigatran is a direct thrombin inhibitor.
Idarucizumab is a monoclonal antibody fragment targeting dabigatran.
Indications - a patient being treated with dabigatran with one or more of the following:
(1) need for urgent surgery
(2) need for urgent thrombolysis for stroke
(3) life-threatening or uncontrolled bleeding
Usual dosing: 5 grams (two vials with 2.5 g/vial. each given as a 50 mL infusion)
Anticoagulation reversal: usually within 10 minutes
(2) hypersensitivity reaction
(3) sorbitol intolerance if the patient has hereditary fructose intolerance
To read more or access our algorithms and calculators, please log in or register.
Specialty: Hematology Oncology